DK3548061T3 - Behandling af neurologiske sygdomme - Google Patents
Behandling af neurologiske sygdomme Download PDFInfo
- Publication number
- DK3548061T3 DK3548061T3 DK17811693.5T DK17811693T DK3548061T3 DK 3548061 T3 DK3548061 T3 DK 3548061T3 DK 17811693 T DK17811693 T DK 17811693T DK 3548061 T3 DK3548061 T3 DK 3548061T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- neurological diseases
- neurological
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1620611.2A GB201620611D0 (en) | 2016-12-05 | 2016-12-05 | Treatment of neurological diseases |
| PCT/GB2017/053655 WO2018104718A1 (en) | 2016-12-05 | 2017-12-04 | Treatment of neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3548061T3 true DK3548061T3 (da) | 2020-12-14 |
Family
ID=58159786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17811693.5T DK3548061T3 (da) | 2016-12-05 | 2017-12-04 | Behandling af neurologiske sygdomme |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11220534B2 (da) |
| EP (1) | EP3548061B1 (da) |
| JP (1) | JP7099729B2 (da) |
| KR (1) | KR102600128B1 (da) |
| CN (1) | CN110312520B (da) |
| AU (1) | AU2017371811B2 (da) |
| BR (1) | BR112019011462A2 (da) |
| CA (1) | CA3044797C (da) |
| CL (1) | CL2019001512A1 (da) |
| CO (1) | CO2019006979A2 (da) |
| CY (1) | CY1123623T1 (da) |
| DK (1) | DK3548061T3 (da) |
| ES (1) | ES2833408T3 (da) |
| GB (1) | GB201620611D0 (da) |
| HR (1) | HRP20201959T1 (da) |
| HU (1) | HUE052766T2 (da) |
| LT (1) | LT3548061T (da) |
| MX (1) | MX2019006495A (da) |
| PT (1) | PT3548061T (da) |
| RS (1) | RS61230B1 (da) |
| RU (1) | RU2755997C2 (da) |
| SI (1) | SI3548061T1 (da) |
| SM (1) | SMT202000684T1 (da) |
| WO (1) | WO2018104718A1 (da) |
| ZA (1) | ZA201903003B (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201620611D0 (en) * | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| CA3154744A1 (en) | 2019-11-06 | 2021-05-14 | Sarah FRIEDRICH | Glp-1 receptor agonists in dementia |
| TW202228762A (zh) * | 2020-01-30 | 2022-08-01 | 美商美國禮來大藥廠 | 提派肽(tirzepatide)之治療用途 |
| MX2023000303A (es) | 2020-07-22 | 2023-02-09 | Novo Nordisk As | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. |
| JP2023543036A (ja) * | 2020-09-25 | 2023-10-12 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体またはその結合体の神経退行性疾患の治療用途 |
| CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| IL308392A (en) | 2021-05-13 | 2024-01-01 | Carmot Therapeutics Inc | G protein-coupled receptor modulators |
| CN114042149B (zh) * | 2021-12-03 | 2023-06-16 | 中国人民解放军空军军医大学 | D-Ala2-GIP用于制备治疗焦虑症药物的应用 |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| WO2023151594A1 (en) * | 2022-02-11 | 2023-08-17 | Hangzhou Sciwind Biosciences Co., Ltd. | A composition comprising gip receptor agonists and glp-1 receptor agonists and use thereof |
| WO2024209050A1 (en) | 2023-04-05 | 2024-10-10 | Antag Therapeutics Aps | Gip activity modulators and orthostatic intolerance |
| CN119925576A (zh) * | 2024-02-06 | 2025-05-06 | 上海市第四人民医院 | 一种治疗神经退行性疾病的药物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545933A3 (en) | 2006-01-05 | 2013-04-24 | University Of Utah Research Foundation | Methods and compositions related to improving properties of pharmacological agents targeting nervous system |
| DK2300035T3 (da) | 2008-06-17 | 2015-11-16 | Univ Indiana Res & Tech Corp | Blandede GIP-baserede agonister til behandling af metaboliske sygdomme og obesitet |
| BRPI0920209A2 (pt) | 2008-10-15 | 2015-12-22 | Angiochem Inc | conjugados de agonistas de glp-1 e usos dos mesmos |
| EP2528618A4 (en) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| UA114592C2 (uk) | 2010-09-28 | 2017-07-10 | Ноно Інк. | Пептид nd2 та спосіб лікування неврологічного захворювання |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| EP2766094B1 (en) | 2011-10-10 | 2019-03-06 | Lancaster University Business Enterprises Limited | Compositions for binding to amyloid proteins |
| JP6228187B2 (ja) | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| CA2877358A1 (en) * | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| WO2015181756A1 (en) | 2014-05-28 | 2015-12-03 | Nono Inc. | Chloride salt of tat-nr2b9c |
| GB2528436A (en) * | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| US20160143920A1 (en) * | 2014-10-22 | 2016-05-26 | Morris Notelovitz | Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging |
| US20170112897A1 (en) | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
| EP3368556B1 (en) | 2015-10-28 | 2024-04-10 | Tufts University | Novel polypeptides with improved proteolytic stability, and methods of preparing and using same |
| WO2017210168A1 (en) | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Aqueously soluble and chemically stable depsi glucagon agonists |
| GB201620611D0 (en) * | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
-
2016
- 2016-12-05 GB GBGB1620611.2A patent/GB201620611D0/en not_active Ceased
-
2017
- 2017-12-04 DK DK17811693.5T patent/DK3548061T3/da active
- 2017-12-04 ES ES17811693T patent/ES2833408T3/es active Active
- 2017-12-04 RU RU2019118165A patent/RU2755997C2/ru active
- 2017-12-04 HR HRP20201959TT patent/HRP20201959T1/hr unknown
- 2017-12-04 BR BR112019011462A patent/BR112019011462A2/pt unknown
- 2017-12-04 SM SM20200684T patent/SMT202000684T1/it unknown
- 2017-12-04 LT LTEP17811693.5T patent/LT3548061T/lt unknown
- 2017-12-04 JP JP2019529926A patent/JP7099729B2/ja active Active
- 2017-12-04 CN CN201780075565.8A patent/CN110312520B/zh active Active
- 2017-12-04 RS RS20201491A patent/RS61230B1/sr unknown
- 2017-12-04 EP EP17811693.5A patent/EP3548061B1/en active Active
- 2017-12-04 US US16/466,194 patent/US11220534B2/en active Active
- 2017-12-04 PT PT178116935T patent/PT3548061T/pt unknown
- 2017-12-04 WO PCT/GB2017/053655 patent/WO2018104718A1/en not_active Ceased
- 2017-12-04 SI SI201730543T patent/SI3548061T1/sl unknown
- 2017-12-04 HU HUE17811693A patent/HUE052766T2/hu unknown
- 2017-12-04 AU AU2017371811A patent/AU2017371811B2/en active Active
- 2017-12-04 CA CA3044797A patent/CA3044797C/en active Active
- 2017-12-04 KR KR1020197015601A patent/KR102600128B1/ko active Active
- 2017-12-04 MX MX2019006495A patent/MX2019006495A/es unknown
-
2019
- 2019-05-14 ZA ZA2019/03003A patent/ZA201903003B/en unknown
- 2019-06-04 CL CL2019001512A patent/CL2019001512A1/es unknown
- 2019-06-27 CO CONC2019/0006979A patent/CO2019006979A2/es unknown
-
2020
- 2020-12-09 CY CY20201101167T patent/CY1123623T1/el unknown
-
2021
- 2021-10-13 US US17/500,430 patent/US11851468B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3548061T3 (da) | Behandling af neurologiske sygdomme | |
| DK3777855T3 (da) | Fremgangsmåder til behandling af fibrotiske sygdomme | |
| DK3728271T3 (da) | Makrocykliske forbindelser til behandling af sygdomme | |
| DK3448999T3 (da) | Oligonukleotider til behandling af øjensygdom | |
| DK3450553T3 (da) | Mrna-terapi til behandling af øjensygdomme | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3851537T5 (da) | Behandling af hyperbilirubinæmi | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3609529T3 (da) | Rna til behandling af autoimmune sygdomme | |
| DK3458052T3 (da) | Kombinationsbehandling af cancer | |
| DK3419622T3 (da) | Behandling af neurodegenerativ øjensygdom med pridopidin | |
| DK3210973T3 (da) | Heteroarylforbindelser til behandling af oftalmiske sygdomme | |
| IL257764B (en) | Methods for treatment of diseases | |
| DK3192524T3 (da) | Hgf præparat egnet til behandling af neurologiske lidelser | |
| DK3430143T3 (da) | Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| LT3119384T (lt) | Intrahepatinių cholestazinių ligų gydymas | |
| DK3578562T3 (da) | L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| IL263080B (en) | Treatment of neurological disorders | |
| DK3848028T3 (da) | Fremgangsmåder til behandling af øjenlidelser | |
| DK3182980T3 (da) | Behandling af glykosyleringsmangelsygdomme | |
| IL259381B (en) | Mirabegron for the treatment of retinal diseases |